07:00 , Sep 30, 2002 |  BC Week In Review  |  Company News

AvMax, Lyotropic Therapeutics Inc. deal

Lyotropic received a license to AvMax's patents covering the use of essential oils and related natural compounds to improve the oral absorption or bioavailability of therapeutics. Lyotropic will use the IP in the development of...
07:00 , Jun 25, 2001 |  BC Week In Review  |  Company News

Ontogen management update

Ontogen Corp. , Carlsbad, Calif.   Business: Cancer, Autoimmune/Inflammation   Appointed: Jeff Riley as VP of strategy and corporate development, formerly COO at AvMax, Inc.  ...
07:00 , Apr 2, 2001 |  BioCentury  |  Tools & Techniques

VEGF: Connecting SNPs with CYPs

The family of cytochrome P450 (CYP) enzymes, which affect drug metabolism, are providing a fertile playground in the field of individualized medicine. Last week researchers published that a particular polymorphism in the gene for the...
07:00 , Apr 24, 2000 |  BC Week In Review  |  Clinical News

Oral bioavailability technology regulatory update

The University of California (Oakland, Calif.) received U.S. Patents Nos. 6,004,927 and 6,028,054 covering the use of inhibitors of cytochrome P450 3A ( CYP3A ) or P-glycoprotein (Pgp), respectively, to increase the bioavailability of orally...
07:00 , Apr 13, 1998 |  BC Week In Review  |  Clinical News

AvMax regulatory update

AvMax received U.S. Patent Nos. 5,665,386 and 5,716,928 covering the use of essential oils and their components to improve the oral absorption of pharmaceutical compounds. AvMax said the oils inhibit drug metabolism in cells lining...
08:00 , Jan 26, 1998 |  BioCentury  |  Finance

Vivus bowls over NBC

Ebb & Flow NBC's refusal to air Vivus' commercial for its MUSE erectile dysfunction product during the Super Bowl may be a blessing in disguise. The company is ramping up a print and TV advertising...